Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02195869 · FLOW

Participant flow

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease · Source last updated 2019-07-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Subjects receive daily dose of 420 mg of Ibrutinib capsules
    id
    FG000
    title
    Phase 1b/Phase 2
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      cGVHD Progression
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Malignancy Progression/relapse
    3. reasons
      1. group Id
        FG000
        num Subjects
        15
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Withdrawal by Subject
    5. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Physician Decision
    6. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Study Terminated by Sponsor
    7. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Noncompliance with study drug
    milestones
    1. achievements
      1. comment
        Phase 1b: 6 patients, 420 mg, no DLT observed. Phase 2: 42 patients, 420 mg
        group Id
        FG000
        num Subjects
        42
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        42
      type
      All-Treated Population
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        42
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Subjects receive daily dose of 420 mg of Ibrutinib capsules
    id
    FG000
    title
    Phase 1b/Phase 2
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      cGVHD Progression
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Malignancy Progression/relapse
    3. reasons
      1. group Id
        FG000
        num Subjects
        15
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Withdrawal by Subject
    5. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Physician Decision
    6. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Study Terminated by Sponsor
    7. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Noncompliance with study drug
    milestones
    1. achievements
      1. comment
        Phase 1b: 6 patients, 420 mg, no DLT observed. Phase 2: 42 patients, 420 mg
        group Id
        FG000
        num Subjects
        42
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        42
      type
      All-Treated Population
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        42
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice